Now could be a great time to scoop up three stocks trading way below their previous peaks.
These dividend payers could more than double their payouts in the decade ahead.
Analysts are quite bullish about these beaten-down stocks.
The company scored a $1 billion upfront payment for expanding a commercial partnership.
These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, and Royalty...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired an interest...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of...
Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million...